|1.||Yao, Mu: 2 articles (10/2015 - 07/2010)|
|2.||Sved, Paul: 2 articles (10/2015 - 07/2010)|
|3.||Dong, Qihan: 2 articles (10/2015 - 07/2010)|
|4.||Teng, Ying: 1 article (10/2015)|
|5.||Xie, Chanlu: 1 article (10/2015)|
|6.||Witting, Paul: 1 article (10/2015)|
|7.||Holst, Jeff: 1 article (10/2015)|
|8.||Wang, Qian: 1 article (10/2015)|
|9.||Tiffen, Jessamy: 1 article (10/2015)|
|10.||Bao, Shisan: 1 article (10/2015)|
|1.||Prostatic Neoplasms (Prostate Cancer)
10/27/2015 - "Moreover, a pre-treatment of the prostate cancer cells with Efipladib during induction of cell cycle re-entry subsequently compromised their tumorigenic capacity in vivo. "
07/01/2010 - "Inhibition of cPLA(2)alpha expression by siRNA or activity by Efipladib in prostate cancer cell lines (PC3 and LNCaP) led to an increase in COX-1 protein and PGE(2) levels in a dose-dependent manner from 24 to 72 h. "
03/01/2011 - "Since efipladib appears to have limited permeation of the blood-brain barrier, we used this compound to determine the extent of pain reversal resulting primarily from peripheral, but not central, inhibition of the arachidonic acid (AA) pathway. "
03/01/2011 - "The contribution of central PGE(2) levels to the nociceptive response in rats was assessed and the effects of the selective cPLA(2)α inhibitor efipladib, and pain therapies of different classes on these responses was determined. "
|1.||Prostaglandins E (PGE)
|2.||Small Interfering RNA (siRNA)
|3.||Arachidonic Acid (Vitamin F)